UBS Raises Healthcare Realty Trust Price Target to $20 From $18
UBS maintained its Neutral rating. The change follows the company’s third-quarter 2026 earnings report, which included updates on normalized FFO and full-year guidance.
UBS maintained its Neutral rating. The change follows the company’s third-quarter 2026 earnings report, which included updates on normalized FFO and full-year guidance.